Tiny separations at heart cell connections that may cause arrhythmias

Arrhythmia Mechanisms Modulated by Intercalated Disc Extracellular Nanodomains

NIH-funded research Virginia Polytechnic Inst and St Univ · NIH-11293399

This project looks at whether tiny separations between heart cells make dangerous heart rhythms more likely in people with Brugada syndrome or arrhythmogenic cardiomyopathy.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionVirginia Polytechnic Inst and St Univ NIH-funded
Lab location1 site (Blacksburg, United States)
Project IDNIH-11293399 on NIH RePORTER

What this research studies

The team is examining how small gaps at the connections between heart muscle cells (the intercalated disc) change electrical signals in the heart. They will use lab tissue and animal models to create swelling in the heart and test whether that swelling reveals hidden problems in sodium channels and junction proteins linked to Brugada syndrome and arrhythmogenic cardiomyopathy. The researchers will compare different experimental conditions that can mask or unmask conduction problems, with special attention to the right ventricle where these diseases often appear. Their work aims to see if managing these tiny cell separations or tissue swelling could prevent dangerous arrhythmias.

Who could benefit from this research

Good fit: People diagnosed with Brugada syndrome or arrhythmogenic cardiomyopathy, especially those with right‑ventricle involvement or known mutations affecting intercalated disc proteins, would be the most relevant candidates.

Not a fit: Patients whose arrhythmias are caused mainly by other conditions (such as coronary artery disease or structural heart problems unrelated to intercalated disc proteins) are less likely to benefit directly from this project.

Why it matters

Potential benefit: If successful, this work could point to new ways to prevent or reduce life‑threatening arrhythmias by targeting cell‑to‑cell connections or controlling heart tissue swelling.

How similar studies have performed: Previous laboratory studies have shown that electrolyte environment and gap‑junction proteins like connexin43 can hide or reveal conduction defects, but applying these findings to Brugada syndrome and arrhythmogenic cardiomyopathy in intact tissue is a newer approach.

Where this research is happening

Blacksburg, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Brugada syndrome
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.